- Conditions
- Recurrent Glioblastoma
- Interventions
- Carboplatin, Exablate BBBD
- Drug · Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- DMG, DIPG
- Interventions
- TAA-T Cell, BBB Disruption
- Biological · Device
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Glioblastoma, Glioma, Liquid Biopsy
- Interventions
- Focused Ultrasound (Exablate Model 4000)
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Newport Beach, California • San Francisco, California + 11 more
- Conditions
- Glioma
- Interventions
- ExAblate 4000 - Type 2
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Brain Tumor
- Interventions
- Exablate, Doxorubicin
- Device · Drug
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Fort Worth, Texas
- Conditions
- Brain Tumor
- Interventions
- InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alzheimer Disease
- Interventions
- Blood Brain Barrier (BBB) Disruption
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 10
- States / cities
- Delray Beach, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 7 more
- Conditions
- Glioma
- Interventions
- Exablate BBBD
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 21 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Houston, Texas
- Conditions
- Glioma, Glioblastoma
- Interventions
- Focused ultrasound (FUS)
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease 1
- Interventions
- Aducanumab, Exablate Model 4000 Type 2, Lecanemab
- Drug · Device
- Lead sponsor
- Ali Rezai
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia